Back to overview

Chemical proteomics for the discovery of glioma stem cell markers

English title Chemical proteomics for the discovery of glioma stem cell markers
Applicant Pedretti Marta
Number 118729
Funding scheme Marie Heim-Voegtlin grants
Research institution Institut für Pharmazeutische Wissenschaften ETH Zürich
Institution of higher education ETH Zurich - ETHZ
Main discipline Experimental Cancer Research
Start/End 01.01.2008 - 30.04.2010
Approved amount 123'940.00
Show all

All Disciplines (3)

Experimental Cancer Research
Neurophysiology and Brain Research
Pharmacology, Pharmacy

Keywords (6)

brain tumors; neural cancer stem cells; cellular markers; proteomics; therapeutic antibodies; targeted therapy

Lay Summary (English)

Lay summary
The majority of tumors of glial cell origin have a fast and fatal outcome. There is growing evidence that most malignancies originate from a stem cell that has accumulated alterations able to transform it into a cancer stem cell.A brain tumor stem cell population has recently been described, but its cellular characterization is still missing. The identification of accessible membrane markers is a fundamental biomedical goal, both for the understanding of tumor biology and for the development of antibody-based therapies. In this Project, I plan to capitalize on my previous research in INSERM U711 laboratory (Prof. Dr. J-Y Delattre, Paris, FR) for the isolation of glioma stem cells, and on the proteomic and antibody-phage technologies available in Prof. D. Neri group at ETHZ for the identification of glioma stem cell specific markers and for the generation of human monoclonal antibodies selectively recognizing them in vitro and in vivo.
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants